How to Buy Relay Therapeutics Stock
Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
Relay Therapeutics stock last closed at $6.37, up 3.49% from the previous day, and has decreased 44.07% in one year. It has underperformed other stocks in the Biotechnology industry by 0.22 percentage points. Relay Therapeutics stock is currently +11.75% from its 52-week low of $5.70, and -52.18% from its 52-week high of $13.32.
As of Apr 26, 2024, there are 131.18M RLAY shares outstanding. The market capitalization of RLAY is $835.61M. In the last 24 hours, 769,750 RLAY shares were traded.
How to Buy Relay Therapeutics Stock
Not sure how to invest in Relay Therapeutics stock? Here's how.
- Figure out where to buy Relay Therapeutics stock: You need to pick an online brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you choose where to buy Relay Therapeutics stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Put funds into your investment account: Select your method of payment and add your information.
- Research Relay Therapeutics stock: The Relay Therapeutics ticker symbol is RLAY. Is Relay Therapeutics stock a good investment? Should you buy shares of RLAY? How do RLAY's underlying business fundamentals look? Do top analysts think Relay Therapeutics is a good buy? Why has RLAY's stock price moved recently? (Hint: Our stock market research website can help you understand if RLAY is a good stock to buy).
- Execute your RLAY purchase: Decide if you will purchase RLAY shares at the current market price or use a limit order to buy RLAY stock at a given price.
- Keep an eye on your investment in RLAY: Create a watchlist to keep track of your new investment in Relay Therapeutics shares.
Step 1: Figure out where to buy Relay Therapeutics stock
You will need an online brokerage account in order to access the NASDAQ market and buy RLAY stock.
Our favorite brokerage: eToro
We believe that eToro is the best brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world financial markets: From Technology to Industrials, New York to Hong Kong — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro boasts a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by signing up for an account with eToro today.
Open eToro AccountStep 2: Open a brokerage account
Now that you've chosen your brokerage, it's time to fill out some personal details so you can invest in RLAY stock today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to open your new brokerage account.
- Submit your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've finished signing up on apps for stocks, you need to deposit funds:
Check out the tutorial below to see the process of depositing funds into your brokerage account.
Step 4: Research Relay Therapeutics stock
Once you have selected the best place to buy Relay Therapeutics stock, it's critical to research their stock before you buy, so you actually understand the risk as well as the upside.
Relay Therapeutics stock at a glance
Relay Therapeutics Overview
WallStreetZen was created to help everyday investors perform more in-depth fundamental analysis quickly.
You can see all of the due diligence checks on RLAY's stock page.
Is RLAY stock overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge RLAY's fair value.
Using relative valuations methods:
- RLAY could be undervalued based on its P/B ratio of 1.11x, relative to Biotechnology industry P/B ratio of 5.85x
You can do additional valuation research on RLAY's stock here.
RLAY Financial Overview
Passed Financial Due Diligence Checks:
- RLAY has a low debt to equity ratio of 0.12.
- There are more short-term assets than short-term liabilities on the RLAY balance sheet.
- Total RLAY debt is lower than 5 years ago, relative to shareholder equity.
- RLAY has cash burn of 304442000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the RLAY balance sheet.
- RLAY has $752.79M in cash and short term investments. This is enough to cover its annual cash burn of $304.44M.
Failed Financial Due Diligence Checks:
- RLAY profit margin has gone up by 196.97 percentage points in the past year, but the company is still unprofitable.
Do Wall Street analysts think it's a good time to buy Relay Therapeutics stock
Out of 2 Equities analysts who give recommendations on RLAY, the consensus analyst rating on RLAY is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
You can dig deeper into what analysts are saying on the Relay Therapeutics stock forecast page.
RLAY Technicals
RLAY Performance Metrics
Last year, RLAY revenue was $25.55M. In the last 3 year, RLAY's revenue has increased by -88.41% per year. This was slower than the Biotechnology industry average of 28.56%.
Learn more about RLAY's earnings and revenue performance here.
Are RLAY insiders buying or selling the stock?
Over the last year, executives and large shareholders at RLAY have sold more shares than they have bought.
Brian Adams, Chief Legal Officer of RLAY, was the latest RLAY insider to sell. They sold $2,679.60 worth of RLAY stock on Mar 27, 2024.
Learn more about who owns RLAY shares here.
Can I rely on RLAY as an income stream?
No, Relay Therapeutics doesn't provide an income stream by paying out dividends.
RLAY Social Trading Data
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Execute your RLAY purchase
You have two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly fine. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a given price limit, use a limit order.
Press the Open button and your broker will execute the order.
If you need more info about buying stocks on eToro, click the helpful video below:
Step 6: Keep an eye on your investment in RLAY
Now that you own some RLAY shares, you'll want to stay up-to-date on your new stock purchase.
Create a watchlist to track the most important metrics related to your RLAY stock.
RLAY Feed
How to Buy Stock in Relay Therapeutics
To reiterate, here are the 6 steps to buy Relay Therapeutics stock:
- Figure out where to buy Relay Therapeutics stock
- Open a brokerage account
- Put funds into your investment account
- Research Relay Therapeutics stock
- Execute your RLAY purchase
- Keep an eye on your investment in RLAY
If you require a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Relay Therapeutics, add RLAY to your watchlist by clicking the button below.
Trending Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.